Resistance training and quality of life among men on ADT

A newly published study has added to the mounting evidence that resistance training and related exercises are a valuable complement to medical care for men on androgen deprivation therapy (ADT). … READ MORE …

Introduction of a proposed National Prostate Cancer Council Act

So, according to a communication to its members from the American Urological Association (AUA), U.S. Senators Barbara Boxer (D, CA) and Jeff Sessions (R, AL) have just introduced S. 2813, the National Prostate Cancer Council Act. … READ MORE …

Disulfiram in prostate cancer revisited (this time with copper supplementation)

Not so long ago (back in late 2013), Schweizer et al. reported data from a very small trial of an old drug called disulfiram (also known as Antabuse) in the treatment of men with progressive prostate cancer after first-line therapy. … READ MORE …

Do [11C]choline PET/CT scan data change clinical decision-making?

The practical value of any type of diagnostic and prognostic technology can only really be assessed in the context of whether the data generated by that technology change the way that physicians treat (or make recommendations about treatment for) individual patients. … READ MORE …

Medicare may soon cover Prolaris, Decipher tests for prostate cancer

Both Myriad Genetics and Genome DX Biosciences issued media releases today stating that Medicare contractors have issued draft coverage recommendations for tests used to assess the aggressiveness of prostate cancer based on genetic/genomic analyses of tissue from biopsy and post-surgical samples. … READ MORE …

Neurocrine (small cell) cancer of the prostate: an update

A new review article in the open access journal Oncology offers some key information about neuroendocrine (small-cell) carcinomas of the prostate (and why they offer essential lessons about the diagnosis and management of prostate cancer). … READ MORE …

NICE rejects Provenge as a treatment for mCRPC based on cost

The National Institute for Health and Clinical Excellence (NICE) in the UK has issued a statement that, according to preliminary draft guidelines, it has rejected the use of sipuleucel-T (Provenge) to treat patients with metastatic prostate cancer before they have received chemotherapy. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,154 other followers